Spring Bank Pharmaceuticals, Inc. (SBPH) Given a $29.00 Price Target at Cantor Fitzgerald
SBPH has been the subject of a number of other reports. B. Riley assumed coverage on Spring Bank Pharmaceuticals in a report on Monday, November 6th. They issued a buy rating and a $30.00 price objective for the company. Chardan Capital restated a buy rating on shares of Spring Bank Pharmaceuticals in a report on Sunday, September 17th. Dawson James restated a buy rating on shares of Spring Bank Pharmaceuticals in a report on Monday, August 7th. Finally, ValuEngine downgraded Spring Bank Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Spring Bank Pharmaceuticals has an average rating of Buy and an average price target of $27.25.
Spring Bank Pharmaceuticals (SBPH) traded down $0.25 during midday trading on Thursday, reaching $15.64. The company had a trading volume of 27,560 shares, compared to its average volume of 33,246. Spring Bank Pharmaceuticals has a 1-year low of $6.31 and a 1-year high of $18.93.
ILLEGAL ACTIVITY NOTICE: “Spring Bank Pharmaceuticals, Inc. (SBPH) Given a $29.00 Price Target at Cantor Fitzgerald” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/18/spring-bank-pharmaceuticals-inc-sbph-given-a-29-00-price-target-at-cantor-fitzgerald.html.
Institutional investors have recently modified their holdings of the business. DAFNA Capital Management LLC acquired a new stake in Spring Bank Pharmaceuticals during the 2nd quarter worth about $217,000. C WorldWide Group Holding A S acquired a new stake in Spring Bank Pharmaceuticals during the 2nd quarter worth about $340,000. EAM Investors LLC acquired a new stake in Spring Bank Pharmaceuticals during the 2nd quarter worth about $578,000. Vanguard Group Inc. acquired a new stake in Spring Bank Pharmaceuticals during the 2nd quarter worth about $794,000. Finally, Morse Asset Management Inc grew its holdings in Spring Bank Pharmaceuticals by 156.9% during the 2nd quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock worth $862,000 after acquiring an additional 38,900 shares during the period. Hedge funds and other institutional investors own 28.71% of the company’s stock.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Stock Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.